Trial Profile
A Phase II Open Label Randomised Comparative Multicentre Study to Compare the Efficacy and Tolerability of Olaparib in Combination With Paclitaxel and Carboplatin Versus Paclitaxel and Carboplatin Alone in Patients With Platinum Sensitive Advanced Serous Ovarian Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 01 Feb 2024
Price :
$35
*
At a glance
- Drugs Olaparib (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca; AstraZeneca AB
- 25 Jan 2024 Planned End Date changed from 29 Dec 2023 to 31 Dec 2024.
- 16 Feb 2023 Planned End Date changed from 30 Dec 2022 to 29 Dec 2023.
- 22 Nov 2021 Planned End Date changed from 31 Dec 2021 to 30 Dec 2022.